Verrica Pharmaceuticals Inc. (VRCA)
NCM · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 14.3M | 5.1M | 5.0M | 5.9M |
| Gross Profit | 13.2M | 3.7M | 4.1M | 5.0M |
| Operating Income | 1.6M | (6.9M) | (9.7M) | (11.4M) |
| Net Income | (274K) | (8.1M) | (9.7M) | (13.2M) |
| Diluted EPS | $-0.03 | $-0.57 | $-0.45 | $-0.62 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 9.0M | 5.1M | 7.6M | 35.6M |
| Gross Profit | 8.3M | 4.4M | 4.8M | 32.1M |
| Operating Income | (21.3M) | (63.2M) | (65.8M) | (11.9M) |
| Net Income | (24.5M) | (67.0M) | (76.6M) | (17.9M) |
| Diluted EPS | $-7.20 | $-14.80 | $-14.80 | $-1.68 |